A role for IGF-1R-targeted therapies in small-cell lung cancer?

Hdl Handle:
http://hdl.handle.net/10147/207791
Title:
A role for IGF-1R-targeted therapies in small-cell lung cancer?
Authors:
Gately, Kathy; Collins, Ian; Forde, Lydia; Al-Alao, Bassel; Young, Vincent; Gerg, Michael; Feuerhake, Friedrich; O'Byrne, Kenneth
Affiliation:
Department of Clinical Medicine, Trinity College Dublin, St. James Hospital,, Dublin 8, Ireland. kgately@stjames.ie
Citation:
Clin Lung Cancer. 2011 Jan;12(1):38-42.
Journal:
Clinical lung cancer
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207791
DOI:
10.3816/CLC.2011.n.005
PubMed ID:
21273178
Abstract:
BACKGROUND: Small-cell lung cancer (SCLC) is an aggressive disease with a poor prognosis. The insulin-like growth factor-1 receptor (IGF-1R) is an autocrine growth factor and an attractive therapeutic target in many solid tumors, but particularly in lung cancer. PATIENTS AND METHODS: This study examined tumor samples from 23 patients diagnosed with SCLC, 11 resected specimens and 12 nodal biopsies obtained by mediastinoscopy, for expression of IGF-1R using the monoclonal rabbit anti-IGF-1R (clone G11, Ventana Medical Systems, Tucson, AZ) and standard immunohistochemistry (IHC). RESULTS: All 23 tumor samples expressed IGF-1R with a range of stain intensity from weak (1+) to strong (3+). Ten tumors had a score of 3+, 7 tumors 2+, and 6 tumors 1+. Patient survival data were available for all 23 patients. Two patients died < 30 days post biopsy, therefore, the intensity of anti-IGF-1R immunostaining for 21 patients was correlated to survival. Patients with 3+ immunostaining had a poorer prognosis (P = .003). The overall survival of patients who underwent surgical resection was significantly better (median survival not reached) than patients who were not resected (median survival, 7.4 months) (P = .006). CONCLUSION: IGF-1R targeted therapies may have a role in the treatment of SCLC in combination with chemotherapy or as maintenance therapy. Further studies on the clinical benefit of targeting IGF-1R in SCLC are needed.
Language:
eng
MeSH:
Aged; Blotting, Western; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms/*metabolism/mortality/pathology; Male; Middle Aged; Prognosis; Receptor, IGF Type 1/*biosynthesis; Small Cell Lung Carcinoma/*metabolism/mortality/pathology; Tumor Markers, Biological/*analysis
ISSN:
1938-0690 (Electronic); 1525-7304 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorGately, Kathyen_GB
dc.contributor.authorCollins, Ianen_GB
dc.contributor.authorForde, Lydiaen_GB
dc.contributor.authorAl-Alao, Basselen_GB
dc.contributor.authorYoung, Vincenten_GB
dc.contributor.authorGerg, Michaelen_GB
dc.contributor.authorFeuerhake, Friedrichen_GB
dc.contributor.authorO'Byrne, Kennethen_GB
dc.date.accessioned2012-02-01T10:44:49Z-
dc.date.available2012-02-01T10:44:49Z-
dc.date.issued2012-02-01T10:44:49Z-
dc.identifier.citationClin Lung Cancer. 2011 Jan;12(1):38-42.en_GB
dc.identifier.issn1938-0690 (Electronic)en_GB
dc.identifier.issn1525-7304 (Linking)en_GB
dc.identifier.pmid21273178en_GB
dc.identifier.doi10.3816/CLC.2011.n.005en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207791-
dc.description.abstractBACKGROUND: Small-cell lung cancer (SCLC) is an aggressive disease with a poor prognosis. The insulin-like growth factor-1 receptor (IGF-1R) is an autocrine growth factor and an attractive therapeutic target in many solid tumors, but particularly in lung cancer. PATIENTS AND METHODS: This study examined tumor samples from 23 patients diagnosed with SCLC, 11 resected specimens and 12 nodal biopsies obtained by mediastinoscopy, for expression of IGF-1R using the monoclonal rabbit anti-IGF-1R (clone G11, Ventana Medical Systems, Tucson, AZ) and standard immunohistochemistry (IHC). RESULTS: All 23 tumor samples expressed IGF-1R with a range of stain intensity from weak (1+) to strong (3+). Ten tumors had a score of 3+, 7 tumors 2+, and 6 tumors 1+. Patient survival data were available for all 23 patients. Two patients died < 30 days post biopsy, therefore, the intensity of anti-IGF-1R immunostaining for 21 patients was correlated to survival. Patients with 3+ immunostaining had a poorer prognosis (P = .003). The overall survival of patients who underwent surgical resection was significantly better (median survival not reached) than patients who were not resected (median survival, 7.4 months) (P = .006). CONCLUSION: IGF-1R targeted therapies may have a role in the treatment of SCLC in combination with chemotherapy or as maintenance therapy. Further studies on the clinical benefit of targeting IGF-1R in SCLC are needed.en_GB
dc.language.isoengen_GB
dc.subject.meshAgeden_GB
dc.subject.meshBlotting, Westernen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshHumansen_GB
dc.subject.meshImmunohistochemistryen_GB
dc.subject.meshKaplan-Meier Estimateen_GB
dc.subject.meshLung Neoplasms/*metabolism/mortality/pathologyen_GB
dc.subject.meshMaleen_GB
dc.subject.meshMiddle Ageden_GB
dc.subject.meshPrognosisen_GB
dc.subject.meshReceptor, IGF Type 1/*biosynthesisen_GB
dc.subject.meshSmall Cell Lung Carcinoma/*metabolism/mortality/pathologyen_GB
dc.subject.meshTumor Markers, Biological/*analysisen_GB
dc.titleA role for IGF-1R-targeted therapies in small-cell lung cancer?en_GB
dc.contributor.departmentDepartment of Clinical Medicine, Trinity College Dublin, St. James Hospital,, Dublin 8, Ireland. kgately@stjames.ieen_GB
dc.identifier.journalClinical lung canceren_GB
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.